Montelukast, a cysLTR1 antagonist, is widely used for asthma treatment as an alternative to or in association with Inhaled Corticosteroids (ICS) in steps 3 or 4 of allergic rhinitis treatment, and in the prophylaxis of exercise-induced asthma [31]. The gene discussed is CYSLTR1; the disease is asthma.